Last reviewed · How we verify
CatalYm GmbH — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Associazione Volontari Pazienti Oncologici · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Barts & The London NHS Trust · 1 shared drug class
- Centre Leon Berard · 1 shared drug class
- Centre Oscar Lambret · 1 shared drug class
- Chinese Academy of Medical Sciences · 1 shared drug class
- Chinese Anti-Cancer Association · 1 shared drug class
- Air Force Military Medical University, China · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for CatalYm GmbH:
- CatalYm GmbH pipeline updates — RSS
- CatalYm GmbH pipeline updates — Atom
- CatalYm GmbH pipeline updates — JSON
Cite this brief
Drug Landscape (2026). CatalYm GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/catalym-gmbh. Accessed 2026-06-10.